Recent Company News

• 04:59 PM ET Jun 02, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:02 AM ET May 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:05 AM ET Jun 09, 2025
  

  Ascendis Pharma announced Week 26 interim analysis results from its ongoing COACH Trial ($173.06, 0.00)

• 10:11 PM ET Jun 02, 2025
  

  MHLW grants orphan drug designation to Teijin's navepegritide (TransCon CNP) for the treatment of chondrodysplasia (¥1136.5000, -5.5)

• 09:20 AM ET Jun 02, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:02 AM ET Jun 02, 2025
  

  Ascendis Pharma announces FDA acceptance of FDA TransCon CNP NDA for Priority Review ($162.84, 0.00)

• 12:05 PM ET May 29, 2025
  

  SKYTROFA (lonapegsomatropin) now registered by the TGA for paediatric growth hormone deficiency ($161.38, +2.14)

• 09:43 AM ET May 23, 2025
  

  CORRECTION: Sponsor of Teriparatide Ascend (teriparatide) is Ascend GmbH ($157.97, -2.08)